Sarcoidosis acquires mechanism-targeted therapy after a long quiet period
Efzofitimod late-stage data and other emerging mechanism-targeted programs are reshaping pulmonary sarcoidosis after years of corticosteroid-only first-line.
Pulmonary sarcoidosis has been a corticosteroid-and-immunosuppressant category with limited progress. Efzofitimod (a neuropilin-2-targeted immunomodulator) is in pivotal trials with the proposition of corticosteroid-sparing efficacy. Other mechanism-targeted programs are in earlier-stage trials. The category is at the start of meaningful evolution rather than mid-cycle, but the activity is real.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.